RU2020111305A - Предупреждение и/или лечение нейродегенеративного заболевания - Google Patents

Предупреждение и/или лечение нейродегенеративного заболевания Download PDF

Info

Publication number
RU2020111305A
RU2020111305A RU2020111305A RU2020111305A RU2020111305A RU 2020111305 A RU2020111305 A RU 2020111305A RU 2020111305 A RU2020111305 A RU 2020111305A RU 2020111305 A RU2020111305 A RU 2020111305A RU 2020111305 A RU2020111305 A RU 2020111305A
Authority
RU
Russia
Prior art keywords
composition
zeaxanthin
composition according
omega
fatty acid
Prior art date
Application number
RU2020111305A
Other languages
English (en)
Russian (ru)
Inventor
Алан Норман ГОВАРД
Джон НОЛАН
Риона МАЛКЭХИ
Original Assignee
Говард Фаундейшн Холдингс Лтд
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Говард Фаундейшн Холдингс Лтд filed Critical Говард Фаундейшн Холдингс Лтд
Publication of RU2020111305A publication Critical patent/RU2020111305A/ru

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07Retinol compounds, e.g. vitamin A
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/185Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19Carboxylic acids, e.g. valproic acid
    • A61K31/20Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/56Materials from animals other than mammals
    • A61K35/60Fish, e.g. seahorses; Fish eggs
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biomedical Technology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Psychiatry (AREA)
  • Hospice & Palliative Care (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
RU2020111305A 2017-12-04 2018-05-10 Предупреждение и/или лечение нейродегенеративного заболевания RU2020111305A (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1720119.5A GB201720119D0 (en) 2017-12-04 2017-12-04 Prevention and/or treatment of neurodegenerative disease
GB1720119.5 2017-12-04
PCT/GB2018/051255 WO2019110951A1 (en) 2017-12-04 2018-05-10 Prevention and/or treatment of neurodegenerative disease

Publications (1)

Publication Number Publication Date
RU2020111305A true RU2020111305A (ru) 2022-01-10

Family

ID=60950313

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2020111305A RU2020111305A (ru) 2017-12-04 2018-05-10 Предупреждение и/или лечение нейродегенеративного заболевания

Country Status (15)

Country Link
US (1) US10835509B2 (https=)
EP (2) EP4599891A3 (https=)
JP (2) JP7824729B2 (https=)
KR (1) KR20200095452A (https=)
AU (1) AU2018379644B2 (https=)
BR (1) BR112020005132A2 (https=)
CA (1) CA3071786C (https=)
ES (1) ES3047101T3 (https=)
GB (2) GB201720119D0 (https=)
IE (1) IE87241B1 (https=)
MX (1) MX2020002458A (https=)
RU (1) RU2020111305A (https=)
SG (1) SG11202000786RA (https=)
WO (1) WO2019110951A1 (https=)
ZA (1) ZA202000558B (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR3106957B1 (fr) * 2020-02-07 2024-05-03 Abdelhadi Zahouani Composition alimentaire pour stimuler la fonction cognitive et prevenir et limiter le declin cognitif et la demence chez des sujets adultes ou chez des sujets ages denutris
US12076299B2 (en) * 2020-02-20 2024-09-03 Arjuna Natural Pvt Ltd Composition and method to enhance cognitive support and brain health
JPWO2022244727A1 (https=) * 2021-05-17 2022-11-24
JPWO2024143060A1 (https=) * 2022-12-26 2024-07-04

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2006121421A2 (en) 2004-01-14 2006-11-16 Robert Ritch Methods and formulations for treating glaucoma
US8324276B2 (en) * 2005-01-24 2012-12-04 Pronova Biopharma Norge As Fatty acid composition for treatment of alzheimer's disease and cognitive dysfunction
WO2006116755A2 (en) * 2005-04-28 2006-11-02 Trustees Of Tufts College Synergitic effects of docosahexaenoic acid (dha) and carotenoid absorption of cognitive function
EP2219478B1 (en) * 2007-12-17 2017-05-10 Newtricious B.V. Method of producing egg yolk based functional food product and products obtainable thereby
GB201014340D0 (en) 2010-08-27 2010-10-13 Piraee Mahmood Nutritional supplement formulation comprising saffron and resveratrol
EP3372280B1 (en) * 2011-07-07 2020-09-16 Howard Foundation Holdings Limited Improvements in or relating to visual performance
CN104619313A (zh) * 2012-07-19 2015-05-13 以瓦伦萨国际营业的美国营养品有限公司 磷虾油和反应的虾青素组合物以及相关方法
US20140187648A1 (en) * 2013-01-03 2014-07-03 Howard Foundation Holdings Ltd. Identifying Subjects in Need of Treatment
GB201300055D0 (en) * 2013-01-03 2013-02-20 Howard Foundation Holdings Ltd Identifying subjects in need of treatment
HK1211836A1 (en) * 2013-03-28 2016-06-03 Omniactive Health Technologies Limited Neuroprotective effect of carotenoids in brain
JP6375296B2 (ja) * 2013-07-10 2018-08-15 ライオン株式会社 脳機能改善用内服組成物、脳内アミロイドβ蓄積抑制用内服組成物、脳機能改善用食品組成物及び脳内アミロイドβ蓄積抑制用食品組成物
WO2017144443A1 (en) * 2016-02-22 2017-08-31 Newtricious B.V. Composition for the prevention or treatment of neurodegenerative diseases.

Also Published As

Publication number Publication date
MX2020002458A (es) 2020-07-20
BR112020005132A2 (pt) 2020-09-15
ES3047101T3 (en) 2025-12-03
SG11202000786RA (en) 2020-06-29
GB201720119D0 (en) 2018-01-17
JP2026016698A (ja) 2026-02-03
IE87241B1 (en) 2021-07-07
NZ761512A (en) 2024-01-26
AU2018379644A1 (en) 2020-03-19
GB201807590D0 (en) 2018-06-27
US20190167624A1 (en) 2019-06-06
KR20200095452A (ko) 2020-08-10
EP3644979B1 (en) 2025-08-06
CA3071786C (en) 2023-11-14
ZA202000558B (en) 2021-10-27
JP2021505527A (ja) 2021-02-18
WO2019110951A1 (en) 2019-06-13
EP4599891A2 (en) 2025-08-13
GB2568986A (en) 2019-06-05
IE20180146A1 (en) 2019-06-12
AU2018379644B2 (en) 2024-02-08
CA3071786A1 (en) 2019-06-13
US10835509B2 (en) 2020-11-17
EP3644979A1 (en) 2020-05-06
GB2568986B (en) 2019-12-18
JP7824729B2 (ja) 2026-03-05
EP4599891A3 (en) 2025-10-22

Similar Documents

Publication Publication Date Title
RU2020111305A (ru) Предупреждение и/или лечение нейродегенеративного заболевания
ES2564025T3 (es) Composiciones que comprenden 15-HEPE y métodos de uso de las mismas
US20130108706A1 (en) Dietary formulations
JP2021505527A5 (https=)
JP2016053065A5 (https=)
JP2018517787A5 (https=)
CA3129008A1 (en) Compositions comprising 15-hepe and methods of using the same
JP2017526623A (ja) 活性物質のミネラル・アミノ酸錯体
RS51195B (sr) Upotreba visoko koncentrovanih kompozicija odabranih n-3-masnih kiselina za lečenje poremećaja centralnog nervnog sistema
RU2010120706A (ru) Композиция липоевой кислоты в виде шариков
US9931312B2 (en) Lipid composition for the prevention or treatment of skin problems
JP2023030130A5 (https=)
US20230263736A1 (en) Soft gelatin capsules
KR20080005335A (ko) 치료제
ES2332102T3 (es) Composicion que contiene acidos grasos omega 3 y acidos grasos omega 6.
JP7201646B2 (ja) 経口組成物
ES2964978T3 (es) Ester alquílico del ácido 10-hidroxi-cis-12-octadecenoico y su uso
NZ761512B2 (en) Prevention and/or treatment of neurodegenerative disease
ES2255653T3 (es) Capsula de gelatina con vitaminas liposolubles y acidos grasos.
US12053437B2 (en) Eye health supplement
JP2024545117A5 (https=)
RU2006120614A (ru) Комбинированный продукт из питательных микроэлементов для дополнительной сбалансированной диеты при возрастных дегенеративных изменениях в области желтого пятна
CN109789178B (zh) 影响心血管效率的营养补充剂
GB2504061A (en) Omega-6 Enriched PUFA Phospholipids
Crawford Another Supplement for CAD Prevention Fails